New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer
Study
Multi-center, open lavel study (eNRGy)
|
NRG1 fusion positive NSCLC (n=64) and pancreatic adenocarcinoma (n=30) with disease progression after standard therapy
|
Efficacy
ORR: 33% [22%-46%] in NSCLC; 40% [23% – 59%] in pancreatic cancer
|
Pts with DoR > 6 mos: 43% in NSCLC, 67% in pancreatic cancer
|
Safety
Grade >=3 AEs: Dyspnea (5%), diarrhea (5%), nausea (5%), hemorrhage (5%)
|
FDA Zenocutuzumab Product Label – BLA761352
Reviewed by Ulas D. Bayraktar, MD on Dec 6, 2024